AHR Deficiency Exacerbates Hepatic Cholesterol Accumulation via Inhibiting Bile Acid Synthesis in MAFLD Rats
Open Access
- 29 December 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 349
Abstract
Metabolic-dysfunction-associated fatty liver disease (MAFLD) is a chronic liver disease characterized by abnormal lipid metabolism. The aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor involved in regulating multiple physiological processes. Recent studies have demonstrated that AHR exerts a multifaceted regulatory role in liver diseases by integrating metabolic and immune signaling pathways; however, the specific role of AHR in MAFLD is not clear. In our work, a rat model of MAFLD was established by feeding wild-type (WT) and AHR knockout (AHR−/−) rats with a high-fat, high-fructose, and high-cholesterol diet (HFHFrHCD) for 10 weeks, and then the liver injury markers, lipid-related biochemical indices and liver histopathology were examined to elucidate the effect of AHR on MAFLD progression. We discovered that AHR deficiency can elevate plasma transaminase levels, increase hepatic triglyceride (TG) and total cholesterol (TC), and exacerbate insulin resistance (IR) under an overnutrition environment. Subsequently, liver transcriptome and RT-qPCR were performed to investigate the underlying mechanism, which revealed that the hepatic bile acid synthesis was inhibited because of lower Cytochrome P450 Family 7 Subfamily A Member 1 (CYP7A1) expression in the liver when AHR was knockout. Additionally, intestinal flora dysbiosis occurred in AHR−/− rats fed with HFHFrHCD, which might also contribute to the hepatic cholesterol accumulation. Taken together, our results suggested that AHR might play an important role in regulating cholesterol metabolism by inhibiting bile acid synthesis and breaking the steady state of the gut microbiota during the MAFLD progression.Keywords
Funding Information
- High-level Innovative Research Institute of the Department of Science and Technology of Guangdong Province (2021B0909050003)
This publication has 40 references indexed in Scilit:
- Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implicationsGenes & Diseases, 2025
- Aryl hydrocarbon receptor (AHR) and nuclear factor erythroid-derived 2-like 2 (NRF2): An important crosstalk in the gut-liver axisBiochemical Pharmacology, 2025
- Biomimetic nanoplatform with microbiome modulation and antioxidant functions ameliorating insulin resistance and pancreatic β-cell dysfunction for T2DM managementBiomaterials, 2024
- Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese AdultsClinical Gastroenterology and Hepatology, 2022
- Proteomics and metabolic phenotyping define principal roles for the aryl hydrocarbon receptor in mouse liverActa Pharmaceutica Sinica B, 2021
- Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLDClinical Gastroenterology and Hepatology, 2021
- Pu-erh tea ameliorates obesity and modulates gut microbiota in high fat diet fed miceFood Research International, 2021
- Modulation of aryl hydrocarbon receptor (AHR) and the NAD+-consuming enzyme CD38: Searches of therapeutic options for nonalcoholic fatty liver disease (NAFLD)Biochemical Pharmacology, 2020
- A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancerJournal of Hepatology, 2018
- Aryl Hydrocarbon Receptor Promotes Liver Polyploidization and Inhibits PI3K, ERK, and Wnt/β-Catenin SignalingiScience, 2018